Day: March 28, 2025

Bitget Expands Institutional Lending Services to Support All Spot Trading Pairs

VICTORIA, Seychelles, March 28, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, announced a major upgrade to its Institutional Lending service, enabling institutional clients to borrow funds for trading across all spot trading pairs available on the platform. This strategic enhancement empowers institutional users with greater flexibility and capital efficiency as they explore diversified trading strategies.

The Institutional Lending program offers customized loan packages for professional clients, allowing them to access large-scale liquidity with competitive interest rates. With the latest upgrade, borrowed assets can now be applied to over 800 listed spot tokens on Bitget, significantly expanding the scope of trading and hedging opportunities.

“Institutions play a crucial role in enhancing the liquidity and stability of the crypto market. Expanding our reach among institutional traders is one of Bitget’s core strategies for 2025,” said Gracy Chen, CEO of Bitget. “To navigate the fast-paced nature of crypto, institutions need flexible, scalable, and efficient access to capital. By extending our lending support to all spot pairs, we’re removing operational barriers and empowering institutions to execute sophisticated strategies, hedge risks, and seize opportunities without limitations on asset coverage.”

Bitget offers a seamless and secure institutional lending process. Clients can apply directly through Bitget’s institutional portal, where customized credit lines and terms are determined based on individual profiles and trading history. Currently, Bitget supports USDT as the lending currency, with over 50 types of collateral assets accepted, including BTC, ETH, and USDC. The maximum leverage available is 5x, with loan terms of up to 12 months. In the coming months, Bitget will also expand institutional lending support to include derivatives trading.

This move follows Bitget’s broader commitment to serving institutional clients with world-class infrastructure. Earlier this year, the platform rolled out dedicated OTC services and upgraded custodial solutions in collaboration with licensed partners such as Cobo and Fireblocks, aiming to create a full-stack institutional offering.

More details on Bitget’s Institutional Lending program, will be shared shortly.

About Bitget

Established in 2018, Bitget is the world’s leading cryptocurrency exchange and Web3 company. Serving over 100 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, token swap, NFT Marketplace, DApp browser, and more.

Bitget is at the forefront of driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World’s Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3f9cc1c0-7a38-4b1c-a1c1-834b8c6a6921

GlobeNewswire Distribution ID 1001076711

• Positions Curium as leading manufacturer of Lu-177 isotope
• Brings innovative R&D expertise and pipeline to Curium
• Enhances Curium’s SPECT & PET geographical coverage and supply chain

PARIS, March 28, 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.

The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates, for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval).

Monrol complements and adds to Curium’s extensive research & development (R&D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products. Curium intends to deploy Monrol’s Ga-68 generator globally in the future, pending regulatory approvals.

In addition, Monrol’s PET & SPECT complementary geographic footprint further expands Curium’s offering. The completion of the deal expands Curium’s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium’s vertically integrated production and distribution capabilities.

Mr. Chaitanya Tatineni, Curium’s CEO International Markets commented: “We are delighted to welcome close to 400 highly-skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.”

Mr. Aydin Kucuk General Manager at Monrol added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world-class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium’s global footprint, product portfolio, and track record of innovation.”

Mr. Emin Fadıllıoğlu, CEO, Eczacıbaşı Pharmaceutical and Industrial Investment, said: “We are very proud of our association with Monrol and its transformation in recent years, which today sees them become part of Curium, a world-leader in nuclear medicine. This is a great reflection of the quality of the business, and we believe they will continue to thrive under the ownership of Curium, benefiting from greater access to advanced technology and an extensive global network.”

For more information:

[email protected]

or

Ben Valdimarsson
Reputation Inc
Mob: +44 (0)788 9805930
Email: [email protected]

About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com.

GlobeNewswire Distribution ID 9412464